Sponsors
The bill modernizes and standardizes federal drug testing—explicitly adding methadone and enabling faster updates to detect new threats—to improve safety and clarity for employers, but it raises significant privacy and rights concerns for people on medication-assisted treatment and imposes added compliance costs and rapid deadlines that may burden workers, employers, and taxpayers.
Safety-sensitive federal and transportation workers will be covered by drug tests that explicitly include methadone and are standardized, making test panels clearer for employers and potentially improving on-the-job safety by detecting opioid use where clinically relevant.
HHS will be able to update testing guidance more quickly (annual guidance and short implementation deadlines), allowing faster detection of newly prevalent or dangerous drugs and shortening the time hazardous substances go undetected in safety-sensitive workforces.
Aligning DOT rules with HHS Mandatory Guidelines and standardizing testing panels reduces regulatory confusion for employers, laboratories, and agencies and creates a consistent federal testing approach.
People using methadone for prescription treatment or opioid use disorder (including employees on medication-assisted treatment) may face increased surveillance, stigma, and risk of employment consequences if methadone detection is used punitively rather than accommodated medically.
Expanding routine testing panels and allowing annual additions increases privacy and medical-information surveillance risks for federal and transportation employees because more substances (and therefore more medical inferences) can be detected.
Agencies, employers, and laboratories will incur administrative, compliance, and testing costs (including confirmatory testing), which could raise expenses for employers and taxpayers and create budgetary and operational burdens.
Based on analysis of 5 sections of legislative text.
Introduced March 17, 2026 by Christopher Henry Smith · Last progress March 17, 2026
Adds methadone to federal workplace drug-testing panels and requires annual reviews to add newly identified substances, with DOT required to match HHS updates quickly.
Requires federal workplace drug-testing rules to start testing for methadone and to set up a process for adding other new drugs to testing panels. The Department of Health and Human Services must update the federal Mandatory Guidelines within set deadlines and review them annually; the Department of Transportation must change its workplace testing regulations to match HHS updates on a fast timeline.